Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
As the study of inflammatory bowel disease (IBD) advances, various biological agents for IBD are emerging, ushering in a new area of IBD treatment. Ustekinumab, an anti-interleukin-12/23 agent, is a new option for Crohn's disease patients with prior failure of traditional pharmacological treatm...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Chinês |
| I whakaputaina: |
Chinese General Practice Publishing House Co., Ltd
2022-09-01
|
| Rangatū: | Zhongguo quanke yixue |
| Ngā marau: | |
| Urunga tuihono: | https://www.chinagp.net/fileup/1007-9572/PDF/1658996860121-474947965.pdf |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|